{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:23:45Z","timestamp":1788920625103,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT 159538"],"award-info":[{"award-number":["PJT 159538"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.isci.2023.108628","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T12:24:15Z","timestamp":1701692655000},"page":"108628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Amylin receptor agonism enhances the effects of liraglutide in protecting against the acute metabolic side effects of olanzapine"],"prefix":"10.1016","volume":"27","author":[{"given":"Kyle D.","family":"Medak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Jeromson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalaura","family":"Bellucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan","family":"Arbeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3867-8901","authenticated-orcid":false,"given":"David C.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2023.108628_bib1","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/BF00789054","article-title":"An economic evaluation of schizophrenia-1991","volume":"30","author":"Wyatt","year":"1995","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"10.1016\/j.isci.2023.108628_bib2","series-title":"Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults: A Systematic Review and Meta-Analysis at American Medical Association","author":"Maher","year":"2011"},{"key":"10.1016\/j.isci.2023.108628_bib3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14740338.2020.1713091","article-title":"Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis at Expert","volume":"19","author":"Barton","year":"2020","journal-title":"Opin Drug Saf."},{"key":"10.1016\/j.isci.2023.108628_bib4","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2023.108628_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.isci.2023.108628_bib6","series-title":"Metabolic Syndrome and Obesity Among Users of Second Generation Antipsychotics: A Global Challenge for Modern Psychopharmacology at","author":"Rojo","year":"2015"},{"key":"10.1016\/j.isci.2023.108628_bib7","first-page":"e190013","article-title":"Preclinical and Clinical Sex Differences in Antipsychotic-Induced Metabolic Disturbances: A Narrative Review of Adiposity and Glucose Metabolism","volume":"4","author":"Castellani","year":"2019","journal-title":"J.\u00a0Psychiatr. Brain Sci."},{"key":"10.1016\/j.isci.2023.108628_bib8","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1152\/ajpendo.00164.2018","article-title":"Antipsychotics and glucose metabolism: How brain and body collide at","volume":"316","author":"Kowalchuk","year":"2019","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.isci.2023.108628_bib9","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.eurpsy.2009.01.005","article-title":"Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)","volume":"24","author":"De Hert","year":"2009","journal-title":"Eur. Psychiatry."},{"key":"10.1016\/j.isci.2023.108628_bib10","doi-asserted-by":"crossref","first-page":"104413","DOI":"10.1016\/j.psyneuen.2019.104413","article-title":"Female mice are protected against acute olanzapine-induced hyperglycemia","volume":"110","author":"Medak","year":"2019","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.isci.2023.108628_bib11","doi-asserted-by":"crossref","first-page":"14010","DOI":"10.1096\/fj.201901820R","article-title":"AMPK \u03b21 activation suppresses antipsychotic-induced hyperglycemia in mice","volume":"33","author":"Shamshoum","year":"2019","journal-title":"FASEB J"},{"key":"10.1016\/j.isci.2023.108628_bib12","doi-asserted-by":"crossref","first-page":"E1101","DOI":"10.1152\/ajpendo.00309.2020","article-title":"GLP1 receptor agonism protects against acute olanzapine-induced hyperglycemia","volume":"319","author":"Medak","year":"2020","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.isci.2023.108628_bib13","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1113\/JP282922","article-title":"Fasting or the short-term consumption of a ketogenic diet protects against antipsychotic-induced hyperglycemia in mice","volume":"600","author":"Shamshoum","year":"2022","journal-title":"J. Physiol."},{"key":"10.1016\/j.isci.2023.108628_bib14","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41598-018-19260-x","article-title":"Exercise Protects Against Olanzapine-Induced Hyperglycemia in Male C57BL\/6J Mice","volume":"8","author":"Castellani","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2023.108628_bib15","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1124\/jpet.118.248393","article-title":"AICAR prevents acute olanzapine-induced disturbances in glucose homeostasis","volume":"365","author":"Bush","year":"2018","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.isci.2023.108628_bib16","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1152\/japplphysiol.00876.2020","article-title":"Voluntary physical activity protects against olanzapine-induced hyperglycemia","volume":"130","author":"Shamshoum","year":"2021","journal-title":"J.\u00a0Appl. Physiol."},{"key":"10.1016\/j.isci.2023.108628_bib17","doi-asserted-by":"crossref","first-page":"e22662","DOI":"10.1371\/journal.pone.0022662","article-title":"A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers","volume":"6","author":"Albaugh","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2023.108628_bib18","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/JCP.0b013e31829e8333","article-title":"Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls","volume":"33","author":"Hahn","year":"2013","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.isci.2023.108628_bib19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.psyneuen.2017.05.005","article-title":"Glucagon receptor knockout mice are protected against acute olanzapine-induced hyperglycemia","volume":"82","author":"Castellani","year":"2017","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.isci.2023.108628_bib20","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","article-title":"Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial","volume":"359","author":"Chiasson","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2023.108628_bib21","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jama.290.4.486","article-title":"Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients with Impaired Glucose Tolerance: The STOP-NIDDM Trial","volume":"290","author":"Chiasson","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.isci.2023.108628_bib22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1503\/jpn.110140","article-title":"Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats","volume":"37","author":"Boyda","year":"2012","journal-title":"J.\u00a0Psychiatry Neurosci."},{"key":"10.1016\/j.isci.2023.108628_bib23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/BF00404025","article-title":"Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans","volume":"34","author":"Hartter","year":"1991","journal-title":"Diabetologia"},{"key":"10.1016\/j.isci.2023.108628_bib24","series-title":"Diabetes","first-page":"S233","article-title":"Amylin agonists: A novel approach in the treatment of diabetes","author":"Schmitz","year":"2004"},{"key":"10.1016\/j.isci.2023.108628_bib25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0026-0495(97)90170-0","article-title":"Dose-response for glucagonostatic effect of amylin in rats","volume":"46","author":"Gedulin","year":"1997","journal-title":"Metabolism"},{"key":"10.1016\/j.isci.2023.108628_bib26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.regpep.2006.06.004","article-title":"Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187","volume":"137","author":"Gedulin","year":"2006","journal-title":"Regul. Pept."},{"key":"10.1016\/j.isci.2023.108628_bib27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/dmrr.263","article-title":"Role of amylin in insulin secretion and action in humans: Antagonist studies across the spectrum of insulin sensitivity","volume":"18","author":"Mather","year":"2002","journal-title":"Diabetes. Metab. Res. Rev."},{"key":"10.1016\/j.isci.2023.108628_bib28","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/JCP.0b013e318184b4c5","article-title":"Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration","volume":"28","author":"Chintoh","year":"2008","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.isci.2023.108628_bib29","series-title":"\u03b2-Hydroxybutyrate: A Signaling Metabolite at NIH Public Access","author":"Newman","year":"2017"},{"key":"10.1016\/j.isci.2023.108628_bib30","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1098-2299(199604)37:4<231::AID-DDR5>3.0.CO;2-M","article-title":"Preclinical pharmacology of pramlintide in the rat: Comparisons with human and rat amylin","volume":"37","author":"Young","year":"1996","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.isci.2023.108628_bib31","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.2146\/ajhp050341","article-title":"Pramlintide acetate","volume":"62","author":"McQueen","year":"2005","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.isci.2023.108628_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2042018814558242","article-title":"Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus","volume":"6","author":"Harris","year":"2015","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"10.1016\/j.isci.2023.108628_bib33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/schbul\/sbq053","article-title":"Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents","volume":"38","author":"Albaugh","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.isci.2023.108628_bib34","doi-asserted-by":"crossref","first-page":"113049","DOI":"10.1016\/j.bbr.2020.113049","article-title":"Peripheral mechanisms of acute olanzapine induced metabolic dysfunction: A review of in\u00a0vivo models and treatment approaches","volume":"400","author":"Shamshoum","year":"2021","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.isci.2023.108628_bib35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.psyneuen.2017.12.004","article-title":"Obesity exacerbates the acute metabolic side effects of olanzapine","volume":"88","author":"Townsend","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.isci.2023.108628_bib36","series-title":"Pramlintide,the Synthetic Analogue of Amylin: Physiology, Pathophysiology, and Effects on Glycemic Control, Body Weight, and Selected Biomarkers of Vascular Risk at Dove Press","author":"Hoogwerf","year":"2008"},{"key":"10.1016\/j.isci.2023.108628_bib37","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1054-3589(05)52018-0","article-title":"Tissue Expression and Secretion of Amylin at","volume":"52","author":"Young","year":"2005","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.isci.2023.108628_bib38","series-title":"Pramlintide for the Treatment of Insulin-Requiring Diabetes Mellitus: Rationale and Review of Clinical Data","author":"Kruger","year":"2004"},{"key":"10.1016\/j.isci.2023.108628_bib39","series-title":"GLP-1 Receptor Activated Insulin Secretion from Pancreatic \u03b2-cells: Mechanism and Glucose Dependence at","author":"Meloni","year":"2013"},{"key":"10.1016\/j.isci.2023.108628_bib40","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1038\/s41598-019-44591-8","article-title":"Combined Amylin\/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss","volume":"9","author":"Liberini","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2023.108628_bib41","doi-asserted-by":"crossref","first-page":"E598","DOI":"10.1152\/ajpendo.00419.2016","article-title":"Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog","volume":"313","author":"Gydesen","year":"2017","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.isci.2023.108628_bib42","series-title":"Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease at Elsevier","author":"Baggio","year":"2021"},{"key":"10.1016\/j.isci.2023.108628_bib43","series-title":"The Biology of Incretin Hormones at Cell Metab","author":"Drucker","year":"2006"},{"key":"10.1016\/j.isci.2023.108628_bib44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fnagi.2013.00042","article-title":"Amylin receptor: a common pathophysiological target in Alzheimer\u2019s disease and diabetes mellitus","volume":"5","author":"Fu","year":"2013","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.isci.2023.108628_bib45","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2174\/1381612013397357","article-title":"Amylin Replacement With Pramlintide as an Adjunct to Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: A Physiological Approach Toward Improved Metabolic Control","volume":"7","author":"Weyer","year":"2001","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.isci.2023.108628_bib46","doi-asserted-by":"crossref","first-page":"R945","DOI":"10.1152\/ajpregu.00275.2010","article-title":"Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates","volume":"299","author":"Bello","year":"2010","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.isci.2023.108628_bib47","doi-asserted-by":"crossref","first-page":"78154","DOI":"10.1371\/journal.pone.0078154","article-title":"Improved Glucose Control and Reduced Body Weight in Rodents with Dual Mechanism of Action Peptide Hybrids","volume":"8","author":"Trevaskis","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2023.108628_bib48","series-title":"The Effect of Antipsychotic Treatment on Hormonal, Inflammatory, and Metabolic Biomarkers in Healthy Volunteers: A Systematic Review and Meta-Analysis at Pharmacotherapy","author":"Burghardt","year":"2022"},{"key":"10.1016\/j.isci.2023.108628_bib49","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/schbul\/sbs196","article-title":"Second-generation antipsychotics cause a rapid switch to fat oxidation that is required for survival in C57BL\/6J mice","volume":"40","author":"Klingerman","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.isci.2023.108628_bib50","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/oby.2006.76","article-title":"Temperature dependence of O2 consumption; opposite effects of leptin and etomoxir on respiratory quotient in mice","volume":"14","author":"H\u00f6gberg","year":"2006","journal-title":"Obesity"},{"key":"10.1016\/j.isci.2023.108628_bib51","series-title":"Diabetes","first-page":"508","article-title":"Coordinate regulation of amylin and insulin expression in response to hypoglycemia and fasting","author":"Alam","year":"1992"},{"key":"10.1016\/j.isci.2023.108628_bib52","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/oby.2006.6","article-title":"Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents","volume":"14","author":"Albaugh","year":"2006","journal-title":"Obesity"},{"key":"10.1016\/j.isci.2023.108628_bib53","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/JCP.0b013e3181bfe13e","article-title":"30\u00a0days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice","volume":"29","author":"Coccurello","year":"2009","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.isci.2023.108628_bib54","first-page":"3","article-title":"Atypical antipsychotics: sleep, sedation, and efficacy","volume":"6","author":"Miller","year":"2004","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"10.1016\/j.isci.2023.108628_bib55","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/dom.12148","article-title":"Olanzapine increases hepatic glucose production through the activation of hypothalamic adenosine 5\u2019-monophosphate-activated protein kinase","volume":"15","author":"Ikegami","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.isci.2023.108628_bib56","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/jpet.102.046987","article-title":"Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: A suggested solution based on in\u00a0vivo occupancy","volume":"305","author":"Kapur","year":"2003","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.isci.2023.108628_bib57","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1590\/S0001-37652013005000011","article-title":"Amylin induces hypoglycemia in mice","volume":"85","author":"Guerreiro","year":"2013","journal-title":"An. Acad. Bras. Cienc."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004223027050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004223027050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:49:58Z","timestamp":1787762998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004223027050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2589004223027050"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2023.108628","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amylin receptor agonism enhances the effects of liraglutide in protecting against the acute metabolic side effects of olanzapine","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2023.108628","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"108628"}}